AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2021
Jun 11, 2021
31580_dirs_2021-06-11_2c068e21-06b6-4d56-b5f0-df7905ec99a7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2021-06-09
Reporting Person: Bowden Christopher (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-09 | Common stock | M | 7149 | $39.76 | Acquired | 22636 | Direct |
| 2021-06-09 | Common stock | S | 7149 | $60.1646 | Disposed | 15487 | Direct |
| 2021-06-10 | Common stock | M | 20853 | $39.76 | Acquired | 36340 | Direct |
| 2021-06-10 | Common stock | S | 20853 | $60.0603 | Disposed | 15487 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-09 | Stock option (right to buy) | $39.76 | M | 7149 | Disposed | 2026-02-15 | Common stock (7149.0) | Direct |
| 2021-06-10 | Stock option (right to buy) | $39.76 | M | 20853 | Disposed | 2026-02-15 | Common stock (20853.0) | Direct |
Footnotes
F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.60. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.29. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.